Emerging risk factors for stroke: Patent foramen ovale, proximal aortic atherosclerosis, antiphospholipid antibodies, and activated protein C resistance

Journal of Stroke and Cerebrovascular Diseases

Volumn 6, Issue 4, 1997, Pages 167-172

  Saver, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 16344375465     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-3057(97)80003-1     Document Type: Article

References (32)

1. Sacco R.L., Homma S., and Di Tullio M.R. Patent foramen ovale: A new risk factor for ischemic stroke. Heart Dis Stroke 2 (1993) 235-241
2. Cohnheim J. Handbuch für Artze und Studierende (1877), Hirshwald, Berlin
3. Nighoghossian N., Perinetti M., Barthelet M., Adeline P., and Trouillas P. Transesophageal echocardiography in patients less than 60 years of age without obvious cardiac source of embolism. Neurol Res 17 (1994) 368-372
4. Stollberger C., Slany J., Schuster I., et al. The prevalence of deep venous thrombosis in patients with suspected paradoxical embolism. Ann Intern Med 119 (1993) 461-465
5. Cabanes L., Mas J.L., Cohen A., et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 24 (1993) 1865-1873
6. Homma S., Di Tullio M.R., Sacco R., et al. Characteristics of patent foramen ovale associated with cryptogenic stroke. Stroke 25 (1994) 582-586
7. Stone D.A., Godard J., Corretti M.C., et al. Patent foramen ovale: association between the degree of shunt by contrast transesophageal echocardiography and the risk of future ischemic neurologic events. Am Heart J 131 (1996) 158-161
8. Ende D.J., Chopra P.S., and Rao P.S. Transcatheter closure of atrial septal defect or patent foramen ovale with the buttoned device for prevention of reccurrence of paradoxical embolism. Am J Cardiol 78 (1996) 233-236
9. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. Am Heart J 130 (1995) 1083-1088
10. Toyada K., Yasaka M., Nagata S., and Yamaguchi T. Aortogenic embolic stroke: A transesophageal echocardiographic approach. Stroke 23 (1992) 1056-1061
11. Amarenco P., Duyckaerts C., Tzourio C., Henin D., Bousser M.-G., and Hauw J.-J. The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med 326 (1992) 221-225
12. Amarenco P., Cohen A., Tzourio C., et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 331 (1994) 1474-1479
13. Jones E.F., Kalman J.M., Calafiore P., Tonkin A.M., and Donnan G.A. Proximal aortic atheroma. An independent risk factor for cerebral ischemia. Stroke 26 (1995) 218-224
14. Katz E.S., Tunick P.A., Rusinek H., Ribakove G., Spencer F.C., and Kronzon I. Protruding aortic atheromas predict stroke in elderly patients undergoing cardiopulmonary bypass. J Am Coll Cardiol 20 (1992) 70-77
15. French Study of Aortic Plaques in Stroke Group. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 334 (1996) 1216-1221
16. Hilton T.C., Menke D., and Blackshear J.L. Variable effect of anticoagulation in the treatment of severe protruding atherosclerotic aortic debris. Am Heart J 127 (1995) 1645-1647
17. Swanson S.J., and Cohn L.H. Excision of focal aortic arch atheroma using deep hypothermic circulatory arrest. Ann Thorac Surg 60 (1995) 457-458
18. Geschwind D.H., FizPatrick M., Mischel P.S., and Cummings J.L. Sneddon's syndrome is a thrombotic vasculopathy: neuropathologic and neuroradiologic evidence. Neurology 45 (1995) 557-560
19. Antiphospholipid Antibodies in Stroke Study Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 43 (1993) 2069-2073
20. Khamashta M.A., Cuadrado M.J., Mujic F., Taub N.A., Hunt B.J., and Hughes G.R.V. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332 (1995) 993-997
21. Levine S.R., Brey R.L., Sawaya K.L., et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 38 (1995) 119-124
22. Rosove M., and Brewer P. Antiphospholipid thrombosis: clinical course after first thrombotic event in 70 patients. Ann Intern Med 117 (1992) 303-308
23. Barinagarrementeria F., Cantu-Brito C., De La Pena A., and Izaguirre R. Prothrombotic states in young people with idiopathic stroke: a prospective study. Stroke 25 (1994) 287-290
24. Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thrombosis. Blood 85 (1995) 607-614
25. Zuber M., Toulon P., Marnet L., and Mas J.-L. Factor V Leiden mutation in cerebral venous thrombosis. Stroke 27 (1996) 1721-1723
26. Martinelli I., Landi G., Merati G., Cella R., Tosetto A., and Mannucci P.M. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 75 (1996) 393-394
27. Ridker P.M., Hennekens C.H., Lindpaintner K., Stampfer M.J., Eisenberg P.R., and Miletich J.P. Mutation in the gene coding for coagulation V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 332 (1995) 912-917
28. PR. Catto A., Carter A., Ireland H., et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 15 (1995) 783-785
29. Halbmayer W.-M., Haushofer A., Schon R., and Fischer M. The prevalence of poor anticoagulant response to protein C (APC resistance) among patients suffering from stroke or venous thrombosis and healthy subjects. Blood Coag Fibrinol 5 (1994) 51-57
30. Forsyth P.D., and Dolan G. Activated protein C resistance in cases of cerebral infarction. Lancet 345 (1995) 795
31. van der Bom J.G., Bots M.L., Haverkate F., et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 125 (1996) 265-269
32. Fisher M., Fernandez J.A., Ameriso S.F., Xie D., Gruber A., Paganini-Hill A., and Griffin J.H. Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation. Stroke 27 (1996) 1163-1166